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Neuropathology of Aging in Cats and
its Similarities to Human Alzheimer’s
Disease
Lorena Sordo1*, Alessandra C. Martini 2, E. Fiona Houston1, Elizabeth Head2 and
Danièlle Gunn-Moore1
1The Royal (Dick) School of Veterinary Studies and The Roslin Institute, The University of Edinburgh, Edinburgh, United Kingdom,
2Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA, United States
Elderly cats develop age-related behavioral and neuropathological changes that ultimately
lead to cognitive dysfunction syndrome (CDS). These neuropathologies share similarities
to those seen in the brains of humans with Alzheimer’s disease (AD), including the
extracellular accumulation of ß-amyloid (Aβ) and intraneuronal deposits of
hyperphosphorylated tau, which are considered to be the two major hallmarks of AD.
The present study assessed the presence and distribution of Aβ and tau
hyperphosphorylation within the cat brain (n  55 cats), and how the distribution of
these proteins changes with age and the presence of CDS. For this,
immunohistochemistry was performed on seven brain regions from cats of various
ages, with and without CDS (n  10 with CDS). Cats accumulate both
intracytoplasmic and extracellular deposits of Aβ, as well as intranuclear and
intracytoplasmic hyperphosphorylated tau deposits. Large extracellular aggregates of
Aβ were found in elderly cats, mainly in the cortical brain areas, with occasional
hippocampal aggregates. This may suggest that these aggregates start in cortical
areas and later progress to the hippocampus. While Aβ senile plaques in people with
AD have a dense core, extracellular Aβ deposits in cats exhibited a diffuse pattern, similar
to the early stages of plaque pathogenesis. Intraneuronal Aβ deposits were also observed,
occurring predominantly in cortical brain regions of younger cats, while older cats had few
to no intraneuronal Aβ deposits, especially when extracellular aggregates were abundant.
Intracytoplasmic hyperphosphorylated tau was found within neurons in the brains of
elderly cats, particularly in those with CDS. Due to their ultrastructural features, these
deposits are considered to be pre-tangles, which are an early stage of the neurofibrillary
tangles seen in AD. The largest numbers of pre-tangles are found mainly in the cerebral
cortex of elderly cats, whereas lower numbers were found in other regions (i.e., entorhinal
cortex and hippocampus). For the first time, intranuclear tau was found in both
phosphorylated and non-phosphorylated states within neurons in the cat brain. The
highest numbers of intranuclear deposits were found in the cortex of younger cats,
and this tended to decrease with age. In contrast, elderly cats with pre-tangles had only
occasional or no nuclear labelling.
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INTRODUCTION
In humans, age-related brain changes, such as brain atrophy,
neuronal loss, and vascular pathology, may ultimately lead to
dementia and Alzheimer’s disease (AD) (Raz, 2004; Jack et al.,
2005; Glabe, 2006). The abnormal deposition of senile plaques
containing ß-amyloid (Aβ) and neurofibrillary tangles (NFT)
composed of hyperphosphorylated tau are major pathognomonic
neuropathologies of AD, and are thought to play a key role in its
development (Hardy and Allsop, 1991; Thal et al., 2002; Perl, 2010).
Similarly, aged cats develop age-related cognitive decline and
eventually dementia, which is known as cognitive dysfunction
syndrome (CDS; feline dementia) (Gunn-Moore et al., 2007;
Landsberg et al., 2010). While the neuropathology of this
condition is still poorly understood, several age-related
neurodegenerative changes (i.e., brain atrophy, neuronal loss,
vascular changes, and abnormal protein deposition) are found in
the brains of elderly cats (Head et al., 2005; Gunn-Moore et al., 2006).
β-amyloid is generated from the cleavage of the amyloid
precursor protein (APP) by β and c-secretases. Since cleavage
occurs at different sites, various lengths of Aβ can be formed, with
Aβ40 and Aβ42 being found most commonly in the brain of
patients with AD. While Aβ40 is the most abundant and tends to
accumulate within blood vessels, Aβ42 tends to accumulate in the
extracellular space and form the characteristic senile plaques of
AD (Hardy and Allsop, 1991; Perl, 2010).
Diffuse Aβ aggregates are found in the brains of cats over
10 years of age (Cummings et al., 1996; Nakamura et al., 1996;
Brellou et al., 2005; Head et al., 2005; Gunn-Moore et al., 2006;
Gunn-Moore et al., 2007). Since these deposits do not have dense
cores and share similarities to the diffuse deposits seen in non-
demented humans, it has been suggested that the Aβ deposits
seen in cats are less mature than the characteristic senile plaques
of AD (Cummings et al., 1996; Nakamura et al., 1996; Colle et al.,
2000; Head et al., 2000; Gunn-Moore et al., 2007). Similarly to
human Aβ, deposits in cats are predominantly formed from the
Aβ42 peptide (Cummings et al., 1996; Head et al., 2005). The lack
of Aβ40 in cats may be due to its higher solubility, which
promotes its rapid clearance, impeding its accumulation
within the brain (Hyman et al., 1993; Cummings et al., 1996;
Wisniewski et al., 1996). However, the Aβ40 peptide is found in
association with cerebral blood vessels walls in cats, termed
cerebral amyloid angiopathy (Nakamura et al., 1996). Both the
pattern and distribution of Aβ in cats are more similar to those
found in the elderly, non-demented human brain rather than
patients with AD (Cummings et al., 1996; Nakamura et al., 1996;
Brellou et al., 2005; Head et al., 2005; Gunn-Moore et al., 2007).
Tau is a microtubule-associated protein located in the cytosol
of the cells and provides microtubule stability (Lee et al., 2005;
Kametani and Hasegawa, 2018). When abnormally
hyperphosphorylated, tau aggregates into paired helical
filaments (PHF) that subsequently form NFT (Goedert et al.,
1989; Hardy and Allsop, 1991; Lee et al., 2005; Perl, 2010).
Cats produce similar tau isoforms to those seen in humans
(Chambers et al., 2015); however, there is still controversy
regarding the presence of NFT in the brains of elderly cats. While
some research found no evidence of NFT (Nakamura et al., 1996;
Kuroki et al., 1997), others have reported intracytoplasmic
hyperphosphorylated immunolabelling within neurons, which is
believed to be an early stage of NFT, known as pre-tangles (Head
et al., 2005; Gunn-Moore et al., 2006; Chambers et al., 2015).
The aim of this study was to assess the presence and
distribution of Aβ and tau pathology in the brains of cats of
various ages, with and without CDS. It was hypothesized that
elderly cats would have larger and more frequent extracellular Aβ
deposits and higher numbers of pre-tangles than younger cats. It
was also hypothesized that these changes would be more evident
in cats with CDS.
MATERIALS AND METHODS
Sample Collection
The brains of cats of different ages were collected post-mortem
through the routine necropsy service at The Royal (Dick) School
of Veterinary Studies (RDSVS). Some of these cats were patients
at the RDSVS Hospital for Small Animals, while others came from a
rescue center in Scotland. Most of the cats were affected by old age
and/or chronic disease and were euthanized after veterinary
assessments revealed that further treatment would not benefit
quality of life. A small number of cats were euthanized after
being diagnosed with behavioral problems (e.g., untreatable
aggression) that would impede their rehoming. In all cases, the
owners or shelter manager gave written consent to donate the cats’
bodies for research purposes.
Ethical approval was obtained through the Veterinary Ethical
Review Committee from the RDSVS, The University of
Edinburgh (VERC 50.17 and 30.20).
Some of the patients had been diagnosed with CDS before
euthanasia. For this diagnosis to be made, cats had to have
displayed at least one behavioral change associated with CDS
for at least three months (Gunn-Moore et al., 2007; Landsberg
et al., 2010; Sordo and Gunn-Moore, 2021), and the behavioral
changes could not be attributed to any other medical condition.
After collection, brains were fixed by immersion in 10%
buffered formalin for no less than one week. After fixation,
transversal sections of the brain were taken from the rostral
cortex (Figure 1A), parietal cortex, including hippocampus
(Figure 1B), occipital cortex, including the entorhinal cortex
(Figure 1C), the locus coeruleus and the cerebellum (Figure 1D).
Sections were processed overnight in paraffin (Leica Tissue
Processor ASP300S; Leica Biosystems™) and blocks were made.
Consecutive slices of 6 μm were taken from the blocks using a
microtome (Microtome HM325; Leica Biosystems™) and
mounted on positively charged glass slides (Polysine®, VWR™).
Immunohistochemistry
Consecutive 6 μm sections were taken from the rostral, parietal
(including hippocampus), and occipital (including entorhinal
cortex) lobes, plus of the cerebellum and locus coeruleus.
These regions are those that are typically affected by Aβ and
hyperphosphorylated tau in the AD brain. After deparaffinization
and rehydrating sections, antigen retrieval pre-treatment was
performed by immersing slides in 90% formic acid for 6 h
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(Kraszpulski et al., 1998) for antibody 4G8, and heat incubation
(120°C for 40 min) in sodium citrate buffer (10 mM, pH 6) for all
other antibodies. All antibodies were incubated in 3% hydrogen
peroxide in 10% methanol for 30min to block endogenous
peroxidase activity. Sections were incubated overnight at room
temperature in each of the primary antibodies: two anti-β-amyloid
and six anti-tau antibodies, listed in Table 1. Bound antibody was
detected by incubating slides in biotinylated goat anti-mouse/rabbit
antibodies (1:500; ThermoFisher Scientific™) for one hour, followed
by incubation in ABC peroxidase kit (1:100; ThermoFisher
Scientific™) for 30min. Slides were visualized with 3, 3′-
diaminobenzidine substrate (1:100; DAB; Sigma-Aldrich™) under
light microscope (Nikon™ Brightfield). Negative controls were used
by omitting the primary antibodies. Immunostaining was conducted




To validate that intranuclear immunolabelling was not caused
by artifact or non-specific staining, IHC was performed
following the above protocol and using antibodies with the
same isotypes for AT8 (mouse IgG isotype control;
ThermoFisher Scientific™), AT100 (mouse IgG1 kappa
isotype control; ThermoFisher Scientific™), and A15091A
antibodies (mouse IgG2b kappa isotype control; Biolegend™)
as negative controls.
Dephosphorylation of the tau Protein
To further validate that the intranuclear labelling observed in cat
brains reflected the hyperphosphorylated state of the protein, as
opposed to the non-phosphorylated protein, we used the
approach of dephosphoryling the protein in brain samples. To
achieve this, IHC was performed by following the protocol
described above, for the same hyperphosphorylated tau
antibodies (i.e., AT8, AT100, and A15091A), separately;
however, to dephosphorylate the protein, slides were incubated
in alkaline phosphatase (FastAP Thermosensitive Alkaline
phosphatase; ThermoFisher Scientific™) following
manufacturers’ protocol at 37°C for one hour, followed by
three 5 min washes in fresh bovine serum albumin, before
adding the primary antibodies using the protocol described in
Immunohistochemistry.
FIGURE 1 | Transverse sections of the brain were taken from (A) the rostral cortex; (B) the parietal cortex, including the hippocampus (arrow); (C) the occipital
cortex, including the entorhinal cortex (arrow); and (D) the cerebellum and the locus coeruleus (arrow).
TABLE 1 | Primary antibodies for the detection of ß-amyloid and tau proteins in the cat brain.
Antigen Clone Dilution
Anti-β-amyloid 17–24 and APP (Biolegend™; San Diego, CA) 4G8 1:1,500
Anti-β-amyloid 1–42 (Abcam™; Cambridge, United Kingdom) mOC64 1:6,000
Anti-tau 3-repeat isoform RD3 (Sigma-Aldrich™; Missouri, United States) 8E6/C11 1:1,000
Anti-tau 4-repeat isoform RD4 (Sigma-Aldrich™; Missouri, United States) 1E1/A6 1:1,000
Anti-tau 404–421 (Biolegend™; San Diego, CA Tau46 1:1,000
Phospho-PHF-tau pSer202 + Thr205 (ThermoFisher Scientific™; Massachusetts, United States) AT8 1:200
Purified anti-tau phospho (Ser 262; Biolegend™; San Diego, CA) A15091A 1:1,000
Phospho-PHF-tau pThr212 + Ser214 (ThermoFisher Scientific™; Massachusetts, United States) AT100 1:1,000
Frontiers in Aging | www.frontiersin.org June 2021 | Volume 2 | Article 6846073
Sordo et al. Neuropathology of Aging in Cats
Protein Extraction
Extracts from the cytoplasm, the cytoskeleton, the soluble nuclear
fractions, and the chromatin bound nuclear fractions were
obtained from frozen cat brain tissue (a 10-year-old cat) by
using the Subcellular Protein Fractionation Kit for Tissues
(ThermoFisher Scientific™) following manufacturer’s protocol.
Western Blot
Extracts from the different fractions (15 μl) obtained with the
Subcellular Protein Fractionation Kit for Tissues (ThermoFisher
Scientific™) were prepared in a buffer containing NuPAGE™
LDS Sample Buffer (4x) and NuPAGE™ MES running buffer
(10x) and were loaded into a 12 well NuPAGE™ pre-cast gel,
4–12% bis-tris. The gel ran at 50 V for 20 min, followed by 120 V
for 20 min, and 200 V for 40 min. The proteins were then
transferred onto an Immobilon-FL PVDF membrane
(Millipore™) using a semi-dry electroblotting unit (Trans-
Blot® SD semi-dry transfer cell; Bio-Rad™), run at 0.06 A and
18 V for one hour. The PVDF membrane was transferred into
LICOR blocking buffer (Licor Biosciences™) for one hour.
Primary antibodies were added (AT8, 1:1,000; and Tau46, 1:
5,000), and blots were incubated at 4°C on a roller overnight. Goat
anti-mouse antibodies were used as secondary antibodies (IRdye
680RD; Licor Biosciences™). Analysis was performed using
LICOR odyssey (700 nm wavelength).
Quantification of Protein Deposition
Initially, all of the slides were visually inspected by light
microscopy; this included the slides from the rostral, parietal,
and occipital regions, plus the cerebellum, that had been obtained
after performing IHC with all the eight antibodies.
For the automated quantification of protein deposition, only
the slides stained against mOC64 for ß-amyloid, and AT8 and
AT100 for hyperphosphorylated tau, from all brain regions, were
scanned using a Leica Aperio Versa 200 scanner (Leica
Biosystems™).
Images were transferred to the Aperio eSlide Manager®
v12.4.0.5043 and visualized with the Aperio ImageScope®
v12.3.3.5048. Annotation boxes of 600 μm of width, height and
length were manually placed for each brain region of interest; in
total five annotation boxes were created for gray matter, and five
for white matter; plus, three boxes for hippocampus, and three for
cerebellum. The Positive Pixel Count v9 algorithm was used for
the assessment of positive immunolabelling for the load and
burden (see below) of Aβ and hyperphosphorylated tau. In
addition, the Nuclear Algorithm v9 was used for the
assessment of positive immunolabelling for intranuclear
hyperphosphorylated tau.
Data from the Positive Pixel Count v9 algorithms were
exported to an excel file, where the load (i.e., percentage of
total positive pixels) and burden (i.e., the proportion of the
total area assessed that contains positive labelling) of both ß-
amyloid and hyperphosphorylated tau were calculated, by using
the following equations:
Load of protein (%)  (Nwp + Np + Nsp
Ntotal
)x 100 (1)






Nwp  Number of weak positives.
Np  Number of (moderate) positives.
Nsp  Number of strong positives.
Ntotal  Number of total positives and negatives.
Total area was 1.8 mm2 for cortical regions and 1.08 mm2 for
cerebellum and hippocampus. These area measures were
calculated by multiplying two dimensions of the annotation
boxes (i.e., 600 μm × 600 μm), multiplying the result by the
number of annotation boxes created for each region
(i.e., multiply by five for cortical regions and by three for
hippocampus and cerebellum) and converting the result to mm2.
Data obtained from the Nuclear Algorithm v9, including the
total percentage of nuclei stained and the degree of staining
(i.e., 1 +, 2 +, and 3 +) were exported to an excel sheet and used for
statistical analyses.
Data Analysis
Data were analyzed usingMinitab® v19.2020.1 statistical software
for Windows.
Anderson-Darling tests were performed to assess normality.
Non-normal data were transformed using Box-Cox
transformation or Johnson transformation. Bartlett tests for
equal variances were performed with 95% confidence level
(CI), assuming normal distribution. Non-parametric tests were
performed in the variables in which transformation failed.
To determine whether there were differences in the positive
immunolabelling of proteins (mOC64 for ß-amyloid, and AT8
and AT100 for hyperphosphorylated tau) in the different age
groups, one-way ANOVA were performed assuming equal
variances (if applicable) with two-sided 95% CI and a
significance level of a  0.05. Subsequently, we determined
which group differences were significant using Tukey tests and
Games-Howell post-hoc tests. Kruskal-Wallis tests were
performed to assess differences in non-normal data.
To determine whether there were differences in the positive
immunolabelling of the proteins between gray and white matter,
2-sample t-tests were performed with a 95% CI and a hypothesized
difference of zero, assuming equal variances. Mann-Whitney tests
were performed to assess differences in non-normal data.
To determine whether there were differences in the positive
immunolabelling of the proteins between cats with and without
CDS, 2-sample t-tests were performed as described above.
Finally, chi-square tests were performed to determine whether
there was an association between cognitive status (i.e., cats with
and without CDS) and the presence of pre-tangles.
RESULTS
Demographics
A total of 55 cat brains were collected at necropsy. The majority of
cats were non-pedigree (98.2%; n  54), with only one cat being a
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pedigree breed (a Bengal cat). Half of the cats (52.7%; n  29) were
females; of these, two thirds (69%; n  20) were neutered, and a
third (31%; n  9) were intact. A third of the cats (30.9%; n  17)
were males; most of them (88.3%; n  15) were neutered and only
11.7% (n  2) were intact. The sex of 16.4% (n  9) of the cats was
unknown, mainly because this was not recorded by the
pathologists performing the brain extractions. Ages ranged
between two and 25 years.
Grouping of Cats
Since the precise age of some of the cats was uncertain, cats were
grouped according to their age as Prime (three to six years old),
Mature (seven to 10 years old), Senior (11–14 years old), and
Super Senior (≥15 years old) (Vogt et al., 2017). After being
grouped by age, six cats were in the Prime group; 26 in theMature
group; nine in the Senior group; and 14 in the Super Senior group.
A total of ten cats had a confirmed diagnosis of CDS, eight of
these cats were in the Super Senior group and two were in the
Senior group. (Supplementary material 1).
β-Amyloid Pathology
Cats of all ages showed Aβ pathology (i.e., labeling with 4G8 and
mOC64 antibodies). However, elderly cats (i.e., ≥15 years old)
had more and larger extracellular Aβ deposits than younger cats.
In contrast, younger cats had more positive immunolabelling for
intracytoplasmic Aβ (Table 2) (Figure 2A).
Extracellular Aβ deposition was mostly found in the cortex
regions. These aggregates had a diffuse pattern (Figure 3A)
which, in some cases, formed patches. Congo red and
thioflavin-S staining were negative (data not shown). While
most of the cats showed a diffuse Aβ distribution, one cat had
multiple plaque-like formations (Figure 3B). Both the severity of
pathology and the numbers of cats with extracellular Aβ deposits
increased with age.
Intraneuronal intracytoplasmic Aβ immunolabelling was
found in the younger cats (i.e., three to six years old;
Figure 4) and the percentage of cats with these deposits
decreased with age, particularly in cortex. However, the
opposite was found in the hippocampus, locus coeruleus, and
cerebellum, where the percentage of cats with intracytoplasmic
Aβ immunolabelling increased with age (Figure 2A).
One-way ANOVA were performed to determine whether age
has an effect on Aβ pathology (mOC64 antibody) and to assess
whether there were differences between the age groups. A
statistically significant effect of age on Aβ burden was found
in the rostral cortex (F3  4.55, p  0.005). Tukey tests
TABLE 2 | Percentage of cats from the Prime and Super Senior groups showing intracytoplasmic and extracellular Aβ deposits in the different brain regions, with both 4G8
and mOC64 antibodies.
4G8 antibody mOC64 antibody









Rostral cortex 83% 77% 50% 62% 100% 46% 50% 77%
Parietal cortex 100% 85% 33% 54% 50% 54% 67% 85%
Occipital cortex 100% 85% 33% 62% 83% 62% 67% 85%
Hippocampus 67% 85% 0 8% 33% 46% 0 38%
Locus coeruleus 83% 92% 0 0 17% 62% 0 8%
Cerebellum 83% 92% 0 8% 50% 62% 0 0
FIGURE 2 | Percentage of cats from the Prime and Super Senior groups showing (A) intracytoplasmic and extracellular Aβ deposits in the different brain regions,
with both 4G8 and mOC64 antibodies; and (B) intranuclear labeling of hyperphosphorylated tau (AT8, AT100, and A15091A antibodies) in the different brain regions.
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demonstrated the Prime group had the lowest positive
immunolabelling, when compared to the other age groups.
Statistically significant differences were found between the
Prime and Mature groups (Difference of means  10.24; SE of
difference  2.80; 95% CI [2.94, 17.54]; t  3.66; p  0.002) and
between the Prime and Super Senior groups (Difference of means
 7.93; SE of difference  2.97; 95% CI [0.17, 15.69]; t  2.67; p 
0.043) (Figure 5).
When comparing the Aβ pathology between the different
brain regions, the cerebellum had the lowest load of ß-amyloid
when compared to the other regions (F4  4.58, p  0.001).
Differences in Aβ pathology between gray and white matter
were also assessed. Statistically significant differences in the
positive Aβ labeling were found in all the cortex regions
between gray and white matter, with the strongest
immunolabelling being present in the gray matter (p < 0.001).
To determine whether the extent of Aβ deposits was greater in
cats with CDS, we compared the extracellular Aβ load and burden
in the different brain regions of cats with CDS with that in age-
matched controls. However, 2-sample t-tests showed no
statistically significant differences in the positive Aβ labeling
between cats with and without CDS.
Tau Pathology
Intranuclear and intracytoplasmic immunolabelling of normal
tau (i.e., Tau46 antibody) (Figures 6A,B) is found in cats of all
FIGURE 3 | Extracellular ß-amyloid (Aβ) deposition in the cat brain. (A)Diffuse extracellular Aβ deposition in the parietal cortex of a 12-year-old cat (primary antibody
mOC64), scale bar 20 μm; and (B) Extracellular Aβ plaque-like formation in the parietal cortex of a 16-year-old cat (primary antibody mOC64; scale bar 500 μm).
FIGURE 4 | Intraneuronal intracytoplasmic immunolabelling of ß-amyloid in, (A) the parietal cortex of a 13-year-old cat (primary antibody 4G8); and (B) the occipital
cortex of the same 13-year-old cat (primary antibody mOC64), scale bars 100 μm.
FIGURE 5 | Amyloid-β (Aβ) burden in the rostral cortex of the cats in the
different age groups. Cats in the Prime group had the lowest Aβ burden when
compared to the Mature (p  0.002) and Super Senior groups (p  0.043).
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ages and in all brain regions, as was intracytoplasmic
immunolabelling of the two isoforms of tau: 3 and 4-repeat
(i.e., labelled by 8E6/C11 and 1E1/A6 antibodies, respectively)
(Figures 6C,D).
Intranuclear and intracytoplasmic immunolabelling for
hyperphosphorylated tau (i.e., AT8, AT100, and A15091A
antibodies) was also found within neurons. Intranuclear
immunolabelling was primarily found in younger cats, whereas
intracytoplasmic labelling (i.e., pre-tangles) was found most
frequently in elderly cats (i.e., ≥15 years old).
Intranuclear immunolabelling of hyperphosphorylated tau
was most commonly found in cortical regions of younger cats
(i.e., three to six years old) and the proportion of cats showing
positive immunolabelling tended to decrease with age (Figures
7A,B). In contrast, the percentage of cats showing intranuclear
immunolabelling tended to increase with age in the locus
coeruleus. However, these were not statistically significant
(Table 3) (Figure 2B).
Intracytoplasmic immunolabelling for hyperphosphorylated
tau (i.e., pre-tangles) was found within neurons with all three
FIGURE 6 | Intracytoplasmic immunolabelling of (A) total tau (primary antibody Tau46) in the rostral cortex of a 10-year-old cat, scale bar 20 μm; (B) total tau
(primary antibody Tau46) in the parietal cortex of a 10-year-old cat, scale bar 50 μm; (C) 3-repeat tau isoform tau (primary antibody 8E6/C11) in the hippocampus of a 7-
year-old cat, scale bar 50 μm; and (D) 4-repeat isoform of tau (primary antibody 1E1/A6) in the parietal cortex of a 19-year-old cat, scale bar 50 μm.
FIGURE 7 | Intranuclear immunolabelling of hyperphosphorylated tau in (A) the parietal cortex of a 14-year-old cat (primary antibody AT8), scale bar 20 μm; and (B)
the parietal cortex of a 14-years-old cat (primary antibody AT100), scale bar 20 μm.
Frontiers in Aging | www.frontiersin.org June 2021 | Volume 2 | Article 6846077
Sordo et al. Neuropathology of Aging in Cats
antibodies and its presence was confirmed by Silver-Gallyas
staining (data not shown).
A total of 14 cats were shown to have pre-tangles with the AT8
antibody (Figure 8A). Of these, one was in the Prime group, two in
theMature group, one in the Senior group, and ten in the Super Senior
group. Similarly, 15 cats were shown to have pre-tangles with the
AT100 antibody (Figure 8B), 14 of which also showed positive
staining with AT8. The cat that showed labelling of pre-tangles
with AT100 only was in the Prime group. Of note, the cats that
had pre-tangles showed little to no intranuclear tau immunolabelling.
Six out of ten cats with a confirmed diagnosis of CDS had pre-
tangles labelled by both AT8 andAT100mostly in the cerebral cortex,
and an additional cat with CDS had a similar distribution of pre-
tangles that were labelled by AT100 only. In contrast, labeling of pre-
tangles with the A15091A antibody, which binds to phosphorylated
Ser 262 in human tau, was found in only three cats, one in theMature
group, and two in the Super Senior group. One of the positive cats
from the Super Senior group had a confirmed diagnosis of CDS, and
its pre-tangles were also detected using AT8 and AT100 antibodies.
The proportion of cats in which pre-tangles were detected with
both AT8 and AT100 antibodies increased in all of the brain
regions in the Super Senior group (Figure 9).
One-way ANOVA showed statistically significant differences
in the burden of hyperphosphorylated tau with the AT8 antibody
in the hippocampus (F3  3.08, p  0.036). Tukey tests
demonstrated that the Prime group had a higher burden,
when compared to other age groups. Statistically significant
differences were found between the Prime and Senior groups
(Difference of means  –0.284; SE of difference  0.102; 95% CI
[–0.556, –0.012]; t  –2.77; p  0.038) (Figure 10).
Two-sample t-tests showed statistically significant
differences in the loads of hyperphosphorylated tau between
gray and white matter; higher loads were found in the gray
matter of the rostral (t  2.12, p  0.036) and occipital (t  2.14,
p  0.035) cortices, with AT8 antibody; and in the parietal (t 
2.58, p  0.011) and occipital (t  2.73, p  0.007) cortices, with
AT100 antibody.
The largest numbers of pre-tangles were found in cats with
CDS. Most of these cats (6/10) were shown to have pre-tangles
with both the AT8 and AT100 antibodies in the rostral cortex (X2
 31.534, p < 0.001; and X2  35.224, p < 0.001, respectively), the
parietal cortex (X2  11.6, p  0.001; and X2  19.512, p < 0.001,
respectively), the occipital cortex (X2  22.25, p < 0.001; and X2 
32.245, p < 0.001, respectively), and the hippocampus (X2  8.709,
p  0.003; and X2  11.583, p  0.001, respectively) when
compared with age-matched controls.
It could be argued that the intranuclear hyperphosphorylated
tau may be a consequence of nonspecific binding of the antibody
TABLE 3 | Percentage of cats from the Prime and Super Senior groups showing intranuclear labeling of hyperphosphorylated tau (AT8, AT100, and A15091A antibodies) in
neurons in the different brain regions.
Hyperphosphorylated tau
















Rostral cortex 83 77 83 69 100 92
Parietal cortex 67 85 100 92 100 85
Occipital cortex 83 77 100 85 100 85
Hippocampus 50 54 83 77 83 77
Locus coeruleus 33 54 17 46 83 77
Cerebellum 17 8 33 46 83 77
FIGURE 8 | Pre-tangles of hyperphosphorylated tau in (A) the rostral cortex of a 10-year-old cat (primary antibody AT8), scale bar 50 μm; and (B) the occipital
cortex of a 19-year-old (primary antibodyAT100), scale bar 100 μm.
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to normal tau, hence, a number of controls were included. To
confirm that intranuclear immunolabelling was not caused by
artifact or non-specific staining, IHC was performed using
antibodies with irrelevant specificities but the same isotypes as
AT8, AT100, and A15091A antibodies as negative controls
(Figures 11A,B). To validate that the intranuclear labelling was
detecting hyperphosphorylated tau, it was shown that in tissue
sections dephosphorylated using alkaline phosphatase,
intranuclear immunolabelling of tauwas abolished (Figures 11C,D).
Finally, a Western blot of different subcellular fractions
extracted from a frozen cat brain (a 10-year-old cat) confirmed
the presence of intranuclear hyperphosphorylated tau in both the
soluble nuclear fraction and the chromatin bound fraction using the
AT8 antibody, with a higher level of expression in the soluble nuclear
fraction. Hyperphosphorylated tau was also found in the cytoplasm;
however, it was not detected in the cytoskeletal fraction (Figure 12).
A Western blot using an antibody against total tau (Tau46) gave
similar results, although tau was also found in the cytoskeletal
fraction with this antibody (data not shown).
DISCUSSION
This study shows that elderly cats develop both Aβ and tau
pathologies; with large extracellular Aβ deposits and the presence
of intracytoplasmic pre-tangles of hyperphosphorylated tau
within neurons. Of note, the largest numbers of pre-tangles
were found in the brains of cats with CDS. In contrast,
younger cats generally had more intracytoplasmic Aβ deposits
within neurons, and no pre-tangles; however, they did have
higher intranuclear tau labelling, unlike the older cats.
Aβ Pathology in the Cat Brain and Its
Similarities to AD
Extracellular deposits of Aβ were found in the brains of most of
the cats in this study. While there was some variability between
the individual brains, which also occurs in humans (Braak and
Braak, 1991; Thal et al., 2002), a similar distribution pattern was
observed in most of them (see below).
Cats of all ages had extracellular Aβ deposits; however, the
extent of these deposits varied between age groups. Smaller
deposits were found in younger cats, whereas the largest
deposits were found in cats of the Mature and Super Senior
group, particularly in the rostral cortex. Despite cats in the Prime
group having smaller Aβ deposits than cats in the Senior group,
this was not statistically significant. While this could be due to the
lack of power, it is also possible that Aβ accumulation suddenly
increases, reaching high levels when cats are between 7–10 years
old (Mature group) and then slowly progresses over time.
In the current study, the youngest cat with extracellular Aβ
deposits was four years old; this contradicts previous studies that
only reported Aβ deposits in cats over eight years of age
(Cummings et al., 1996; Head et al., 2005; Gunn-Moore et al.,
2006; Chambers et al., 2015). Extracellular Aβ deposition in cats
in the Prime group was only found in the cortical areas (mainly
rostral cortex with 4G8 labelling, and parietal and occipital
cortices with mOC64). That Aβ deposits start accumulating in
cortical regions in younger cat brains is perhaps not surprising.
According to Braak and Braak, these are the same regions where
Aβ deposition starts in the human brain (i.e., Stage I) (Braak and
Braak, 1991; Thal et al., 2002). In humans, Aβ can begin
accumulating in individuals as young as 20-years-old, based
upon in vivo PET imaging, which is decades before developing
any type of cognitive decline or dementia (Gonneaud et al., 2017).
According to International Cat Care and their equivalence table
between human and cat ages, a cat of four years old correspond to
a human of ∼32 years old (Vogt et al., 2017), so this correlates well
with when Aβ starts accumulating in humans.
FIGURE 9 | Association of the presence of pre-tangles with age in different brain regions with both AT8 (A) and AT100 (B) antibodies.
FIGURE 10 | Cats in the Prime group had a higher burden of
hyperphosphorylated tau with AT8 antibody in the hippocampus when
compared to the Senior group (p  0.038).
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Extracellular Aβ deposits were only found in the hippocampus
in cats in the Super Senior group. Since cats in this age group also
had larger deposits of Aβ in all the cortical brain regions, it is
perhaps logical to conclude that, after accumulating in the cortical
areas, Aβ pathology in cats progresses to the hippocampus. This
same pattern has been described in the human brain during Stage
II of Aβ progression (Braak and Braak, 1991; Thal et al., 2002).
However, more studies are needed to confirm this pattern of
progression in cats.
While the cortical regions and the hippocampus were the
regions most affected by extracellular Aβ deposition in cats, the
cerebellum was least affected. In humans, the cerebellum is only
affected during the final stage of Aβ progression (i.e., Stage V)
(Braak and Braak, 1991; Thal et al., 2002). Hence, it is possible
that these cats did not live long enough to allow progression of Aβ
deposition to the cerebellum.
Larger extracellular Aβ deposits were found affecting gray
matter, when compared to white matter; this was the same in all
cortical regions. This also correlates to the Aβ progression
proposed by Braak and Braak, as gray matter is initially
affected during Stage I, progressing to the white matter during
Stage II of disease (Braak and Braak, 1991).
As has been shown previously, extracellular Aβ deposits in cats
have a diffuse pattern (Head et al., 2005; Gunn-Moore et al., 2006;
Chambers et al., 2015). This may explain why they were not
detected with Congo red or thioflavin-S staining. However, in
some cases, these diffuse deposits did form denser patches. This
distribution pattern, including the occasional formation of
patches, has been previously documented in the cat brain
(Head et al., 2005; Gunn-Moore et al., 2006; Chambers et al.,
2015). Of note, these deposits only contain the Aβ42 peptide
(Cummings et al., 1996; Head et al., 2005).
Diffuse Aβ deposits in humans are mainly formed from this
same peptide (Aβ42); these are believed to be an early stage of
plaques (Hardy and Allsop, 1991; Perl, 2010). Interestingly, one
16-year-old cat in the current study had accumulations of Aβ in
well-defined plaque-like structures. This may be a sporadic
occurrence, which is supported by finding that the oldest cat
in this study (a 25-year-old-cat) had diffuse Aβ deposition but no
plaque-like structures. However, it is also possible that while some
cats can form more compact senile plaques, few of them live long
enough to do so. Further studies are required to confirm this
hypothesis.
No statistically significant difference was found in the presence
and/or extent of Aβ pathology between cats with and without
CDS. This may be due to the low numbers of cats with a
confirmed diagnosis of CDS. It is also plausible that Aβ
pathology in cats does not correlate to the behavioral changes
FIGURE 11 | Confirmation of the specificity of intranuclear immunolabeling for hyperphosphorylated tau. Sections of rostral cerebral cortex from a 14-year-old cat
were labeled by IHC using either AT8 (A) or an isotype control (B) as primary antibody. Intranuclear staining was not seen in the isotype control section (B). Sections of
rostral cerebral cortex from an 18-year-old cat were labeled with AT8 either without (C) or following alkaline phosphatase (AP) treatment (D). No positive intranuclear
staining was seen in the AP treated section (D). Scale bars  20 μm in (A) and 50 μm in (B), (C), and (D).
Frontiers in Aging | www.frontiersin.org June 2021 | Volume 2 | Article 68460710
Sordo et al. Neuropathology of Aging in Cats
related to CDS, as previously suggested (Head et al., 2005). In
humans, there is still contradictory evidence regarding the
correlation between Aβ pathology and cognitive impairment.
It is true that some studies have found a correlation between
Aβ deposition and cognitive decline (Blessed et al., 1968).
However, these studies have some caveats; for instance, they
used silver stains that do not differentiate between senile plaques
and diffuse deposits. In contrast, there is mounting evidence
showing that Aβ pathology does not correlate with cognitive
decline; moreover, there have been individuals with significant
Aβ accumulation and no signs of cognitive impairment (Braak
and Braak, 1996; Aizenstein et al., 2008; Villemagne et al., 2011;
Ricciarelli and Fedele, 2017).
In humans, Aβ deposits accumulate within the cytoplasm of
cells, particularly neurons, as well as in the extracellular spaces.
Intracytoplasmic Aβ deposition is believed to begin at a young
age and to progress with age (Gouras et al., 2000; Baker-Nigh
et al., 2015). For this reason, it has been suggested that
intracellular Aβ has a normal function, potentially as an
antioxidant (Smith et al., 2002; Nunomura et al., 2010).
During early stages, intracytoplasmic Aβ is expressed at low
concentrations and does not produce significant damage
(Volloch et al., 2020); however, as individuals get older, it
continues to accumulate, until it reaches higher concentrations
and becomes toxic (Puzzo and Arancio, 2013). High
concentrations of intracytoplasmic Aβ are linked to
mitochondrial and cytoskeleton dysfunction, plus synaptic
alterations (Gouras et al., 2000; LaFerla et al., 2007; Volloch
et al., 2020). Furthermore, once a neuron dies, Aβ is released into
the extracellular space, where it may promote further Aβ
accumulation (LaFerla et al., 2007). Not surprisingly,
correlations between the amount of intra and extracellular Aβ
have been reported, as intracellular Aβ concentrations tend to
decrease when extracellular deposits accumulate (Mori et al.,
2002; Baker-Nigh et al., 2015).
In the present study, cats of all ages show evidence of
intracytoplasmic Aβ deposition, predominantly within neurons
in cortical areas. When assessing these areas, the proportion of
cats with intracellular immunolabelling was highest in the Prime
group, and it tended to decrease with age, especially where large
extracellular Aβ deposits were found. However, in other areas,
such as the hippocampus, locus coeruleus, and cerebellum, the
proportion of cats with intracytoplasmic Aβ labelling increased
with age. It could be argued that this positive intracytoplasmic
labelling may represent APP, rather than Aβ, as the 4G8 antibody
binds to the residues 17–24 of Aβ, plus APP; however,
intracytoplasmic labelling was also found with the mOC64
antibody, which is a conformation-specific antibody that
recognizes monomers, oligomers, and fibrils of Aβ42.
Furthermore, thioflavin-S staining confirmed the amyloid
structure. As is the case with humans (as discussed above),
these findings suggest that intracytoplasmic Aβ starts
accumulating in cortical areas of the cat brain at a young age,
but then decreases in these regions as cats get older and
extracellular Aβ accumulation increases. Longitudinal studies
are needed to determine the progression of these deposits both
within the cells and in the extracellular spaces, in addition to
looking at the correlation between them. However, given the
current lack of a suitable in vivo methods of doing this, it may be
possible to assess Aβ in the cerebrospinal fluid of cats to
determine the progression of Aβ pathology, which could be
later correlated with the neuropathology.
Tau Pathology in the Cat Brain and Its
Similarities to AD
The current study found that non-phosphorylated tau protein
was present in the brains of cats of all ages using all three tau
antibodies. One of the antibodies, Tau46, binds to the C-terminus
of the protein, while the other two (8E6/C11 and 1E1/A6) bind to
the three and four repeats isoforms of the protein, respectively.
Labelling with these three antibodies showed that tau was highly
FIGURE 12 | Detection of hyperphosphorylated tau in subcellular
fractions extracted from the brain of a 10-year-old cat. Western blotting of
different subcellular fractions, using AT8 as primary antibody, confirmed the
presence of intranuclear hyperphosphorylated tau (AT8 antibody) in the
soluble nuclear (Sol. Nuc.), chromatin-bound nuclear (Chrom. Nuc.) and
cytoplasmic (Cytopl.) fractions but not in the cytoskeleton (Cytosk.).
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expressed in all of the brain regions, in all of the cats at all ages, as
expected. This correlates with the expression of this protein and its
isoforms in the adult human brain (Goedert et al., 1989; Šimić et al.,
2016).
Hyperphosphorylated tau was detected within the cytoplasm
of neurons in some of the cats, using all three antibodies against
hyperphosphorylated tau (i.e., AT8, AT100, and A15091A). Since
these aggregates tended to occupy the whole cytoplasm and yet
appeared in neurons with normal morphology, they are believed
to be pre-tangles (Braak and Del Tredici, 2010), which have been
reported previously in cat brains (Head et al., 2005; Gunn-Moore
et al., 2006; Chambers et al., 2015).
Pre-tangles were primarily observed in the cortex of cats in the
Super Senior group, suggesting that significant tau pathology
starts in cortical regions of the cat brain. If true, this may represent a
difference in the onset of tau pathology between cats and humans, as it
is known to start in the transentorhinal cortex in the latter (Braak and
Braak, 1991). However, since the transentorhinal cortex was not
assessed in the present study, it is impossible to determine whether
tau pathology truly begins in the cortical regions or in the
transentorhinal cortex in this species. In addition to the cortex, one
of the cats in this study, diagnosed with CDS had small numbers of
pre-tangles within their entorhinal cortex.
The load of pre-tangles varied between gray and white matter.
The largest loads of pre-tangles were noted in the rostral and
occipital cortices in gray matter.
Positive immunolabelling for hyperphosphorylated tau was
also found in the hippocampus, where statistically significant
differences were found in the burden between the Prime and
Senior groups, with a higher burden seen in the Prime group, which
was unexpected. However, we noted that the ImageScope image
analysis software cannot distinguish nuclear from cytoplasmic
labeling. If this is true, it is possible that the positive staining seen
in the Prime group corresponds to intranuclear staining, rather than
pre-tangles; after visual inspection of the slides this was found to be the
case, with the intranuclear staining being stronger in the cats in the
Prime group.
Interestingly, few pre-tangles were found in the cortex of two
cats in the Prime group (i.e., one 4-year-old cat and one 6-year-
old cat). Of note, this 4-year-old cat was the same cat that had
extracellular deposition of Aβ. While finding pre-tangles in such
young cats was unexpected, it was not entirely surprising. It is
possible that these cats had undiagnosed neurological disorder
that produced tauopathy, or that their age was miscalculated
(which is not uncommon in cats that come from a rescue shelter),
and they were in fact older than recorded. However, it is also
plausible that tau pathology starts at a young age in some cats.
Braak suggested that the early stages of tau pathology may occur
in younger individuals, as NFT have been found in people under
25 years of age (Braak and Del Tredici, 2010); however, as
individuals get older, the number of NFT increases, leading to
more severe stages of disease (Braak and Del Tredici, 2010).
While no statistically significant differences were found in
either the load or the burden of pre-tangles between cats with and
without CDS, associations were found between the presence of
pre-tangles and CDS; this is nuanced, but important. Finding an
association between the presence of pre-tangles and CDS is not
surprising; half of the cats shown to have pre-tangles had a
confirmed diagnosis of CDS. This was supported by Chi-
square tests that showed that cats with CDS had larger numbers of
pre-tangles, compared to cats without CDS. In humans, a strong
association has been reported between the presence of NFT and
cognitive impairment (Nelson et al., 2012). Furthermore, the
progression stages of tau pathology have been associated with
different stages of cognitive impairment and dementia. While
cognition is known to remain unaffected during Stages I and II, a
mild cognitive impairment has been associated to Stages III and IV
and, finally, AD is associated with the most severe stages of pathology
(i.e., Stages V and VI) (Braak and Del Tredici, 2010).
While there is a plethora of evidence describing the
involvement of NFT in the development of neurodegeneration and
AD, recent studies have shown that these insoluble tau aggregates are
not as toxic as it was originally proposed (Mi and Johnson, 2006;
Mroczko et al., 2019). Instead, it has been suggested that either
monomers or soluble oligomers with abnormal post-translational
modifications, such as acetylation and increased phosphorylation at
specific residues (e.g., acetylation of lysines K174 and K281; and
phosphorylation of Thr231 and Tyr18) play a vital role in causing
neuronal dysfunction (Irwin et al., 2012; Tracy and Gan, 2017;
Neddens et al., 2018; Guha et al., 2020). The role of tau in the
development of AD and cognitive decline remains unclear. On one
hand, tau is believed to be the cause and potential trigger of disease, on
the other, more recent evidence proposes that it plays a protective role
instead (see below).
The presence of intranuclear was first reported in the early
nineties in human neuroblastoma (Loomis et al., 1990;
Greenwood and Johnson, 1995) and other cells, such as
fibroblasts and lymphocytes (Thurston et al., 1996). Of note,
one of these studies found that around 16% of the total tau
protein is located within the nucleus, particularly in the
chromatin (Greenwood and Johnson, 1995).
In the present study, in addition to IHC labelling of intranuclear
tau, Western blots demonstrated that both hyperphosphorylated and
non-phosphorylated states of tau were present in the nuclear fraction
of cat brain extracts. In humans, both states of intranuclear tau are also
known to exist and are believed to have different functions
(Greenwood and Johnson, 1995; Rady et al., 1995).
Studies in rodents have shown that nuclear non-
phosphorylated tau binds and protects DNA after induced
oxidative stress or heat-shock (Papasozomenos and Su, 1991;
Sultan et al., 2011; Maina et al., 2016). These two processes have
been shown to promote the translocation and accumulation of
non-phosphorylated tau into the nucleus and nucleolus in order
to protect and maintain the integrity of DNA (Papasozomenos
and Su, 1991; Sultan et al., 2011). These studies have shown that
there is a significant dephosphorylation of cytoplasmic tau and an
increase in nuclear tau immediately after inducing stress; whereas
the opposite was observed after 24 h, with an increase in
cytoplasmic tau phosphorylation and a decrease in nuclear tau
(Sultan et al., 2011). Because of this, it has been suggested that
phosphorylation may regulate the translocation of tau between
the nucleus and the cytoplasm (Sultan et al., 2011). Furthermore,
abnormal phosphorylation may alter the ability of tau to
translocate and/or may affect its ability to bind to DNA and
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protect it from damage (Lefebvre et al., 2003; Sultan et al., 2011;
Qi et al., 2015; Ulrich et al., 2018).
Nuclear tau is reported in the brains of AD patients, however,
its role in the development of disease remains unclear (Maina
et al., 2016). Following the amyloid cascade hypothesis, Aβ
deposits may promote abnormal phosphorylation of tau,
altering its translocation to the nucleus, and impeding its
binding and protection of DNA (Maina et al., 2016), as
described above.
In the present study, hyperphosphorylated intranuclear tau
was primarily found within the cortical neurons of the cats. However,
while no statistically significant differences were found between the
different age groups, cats in the Prime group tended to have more
hyperphosphorylated intranuclear tau, compared to the older age
groups. The opposite was seen with in the cats that had pre-tangles,
which had little or no intranuclear tau. In contrast, studies in human
brains show that nuclear tau increases with age, reaching the highest
levels at geriatric stages (Gil et al., 2017); however, in AD, intranuclear
tau significantly decreases in the hippocampus and cortex, completely
disappearing in advanced stages of disease (Hernández-Ortega et al.,
2016).
There are a number of limitations to the present study. Since
the neuropathology was only assessed post-mortem, the findings
showed in this study represent a snapshot of the neuropathology
of aging and CDS in cats. Further studies are needed to determine
at what age these changes begin to occur and how the disease
progresses over time. Furthermore, since neither behavioral
changes nor cognition were formally assessed in most of the
cats, no correlations can be evaluated between these and the
presence and/or severity of the neuropathology.
Another limitation arose when trying to trace and retrieve the
cats’ information, particularly where brains were collected several
years before the study started; no information was recorded for
some of the cats (i.e., sex, exact age, or medical record). Having
this information would have helped to understand and/or explain
the neuropathological changes observed in these cats, especially
in the younger ones.
A limitation concerning the sectioning of the brains was also
identified. All brains were manually sectioned by one of the authors
(LS) without using a brain slicer, as had been developed for rats’ and
mice’ brains. This resulted in slight variations in the thickness of the
brain slices. In addition, there were natural individual variation in both
the size and the shape of the brains. Even though anatomical
landmarks were used to minimize variation when slicing the
brains, there were differences in the size of some of the structures
such as the hippocampus and cerebellum. This impeded analyzing
these regions in more detail; for example, since the hippocampus was
not sectioned in the exact same level for all the cats, assessing
differences between the regions within the hippocampus could not
be assessed.
Finally, the inability of the Positive Pixel algorithm to
differentiate between nuclear or cytoplasmic immunolabelling
represents a limitation. Since all the slides were visually inspected
before being scanned, this issue was identified promptly. As a
result of this limitation, and to examine the nuclear
immunolabelling in more detail, the Nuclear algorithm was
used in addition to the Positive Pixel quantification.
In summary, and despite the limitations noted above, the current
study is the largest yet to examine the brains of cats of various ages for
the presence or absence of Aβ and hyperphosphorylated tau deposits.
This study found that cats accumulate Aβ as intracytoplasmic deposits
and diffuse extracellular deposits; in addition, we found
hyperphosphorylated tau within neurons, either as intranuclear or
intracytoplasmic deposits, with the cytoplasm representing pre-
tangles. The extent of extracellular Aβ deposits and the number of
pre-tangles increase with age, as does the percentage of cats with pre-
tangles. Finally, the presence and progression of these pathologies in
terms of their brain location are similar to those seen in humans with
AD, suggesting that the cat has the potential to be a natural model for
the study of this condition.
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